A careful integration of the effectiveness and safety of the therapies for inflammatory bowel disease, considering patients’ disease risks, treatment complications and preferences, is warranted to inform the positioning of therapies in clinical practice. Precision medicine might help choose the best option for an individual patient.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Designing a microbial fermentation-functionalized alginate microsphere for targeted release of 5-ASA using nano dietary fiber carrier for inflammatory bowel disease treatment
Journal of Nanobiotechnology Open Access 23 September 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 /Â 30Â days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bloomgren, G. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870–1880 (2012).
Baumgart, D. C. & Le Berre, C. Newer biologic and small-molecule therapies for inflammatory bowel disease. N. Engl. J. Med. 385, 1302–1315 (2021).
Singh, S. et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis. Lancet Gastroenterol. Hepatol. 6, 1002–1014 (2021).
Solitano, V. et al. Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2022.07.032 (2022).
Burr, N. E. et al. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut 71, 1976–1987 (2022).
Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med. 386, 316–326 (2022).
Biasci, D. et al. A blood-based prognostic biomarker in IBD. Gut 68, 1386–1395 (2019).
Verstockt, B., Parkes, M. & Lee, J. C. How do we predict a patient’s disease course and whether they will respond to specific treatments? Gastroenterology 162, 1383–1395 (2022).
Sazonovs, A. et al. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease. Gastroenterology 158, 189–199 (2020).
Nguyen, N. H., Singh, S. & Sandborn, W. J. Positioning therapies in the management of Crohn’s disease. Clin. Gastroenterol. Hepatol. 18, 1268–1279 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.S.’s institution has received research grants from Pfizer and AbbVie, and S.S. has received personal fees from Pfizer (for ad hoc grant review).
Supplementary information
Rights and permissions
About this article
Cite this article
Singh, S. Positioning therapies for the management of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 20, 411–412 (2023). https://doi.org/10.1038/s41575-023-00744-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-023-00744-9